Who is sponsoring NCT05256576?

NCT05256576 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT05256576?

Interventions in NCT05256576: Implementation of an innovative multi-modal peri-operative care pathway.

What condition does NCT05256576 study?

NCT05256576 studies Ovary Cancer, Fallopian Tube Cancer, Peritoneum Cancer, Frailty.

Is NCT05256576 still recruiting?

NCT05256576 is currently completed. Last updated 15 January 2025.

Last reviewed 2025-01-15 · How we verify

NCT05256576: KORE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients with Ovarian Cancer

Completed NA Last updated 15 January 2025

What this trial tests

NA trial testing Implementation of an innovative multi-modal peri-operative care pathway in Ovary Cancer in 465 participants. Completed in 31 December 2023.

Timeline

1 July 2020

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	465
Start date	1 July 2020
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	2 locations across Germany

Drugs / interventions tested

Implementation of an innovative multi-modal peri-operative care pathway

Conditions studied

Ovary Cancer — all drugs for Ovary Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Peritoneum Cancer — all drugs for Peritoneum Cancer →
Frailty — all drugs for Frailty →

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, female only, with Ovary Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

KORE-INNOVATION is a multi-center clinical study aiming to implement and analyze an innovative care pathway to reduce perioperative complications for patients undergoing surgical treatment for ovarian cancer. This is achieved by a structured, multidisciplinary implementation of the ERAS pathway, as well as introducing a tri-modal prehabilitation program, following a comprehensive frailty-assessment. The patient-individualized prehabilitation program consists of a structured plan to improve physical fitness, nutritional status, as well as patient empowerment. The aim of the study is to reduce perioperative morbidity and mortality, as well as improvement in quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Inci MG, Sehouli J, Schnura E, Lee M, et al · · 2023 · cited 7× · PMID 37208019 · DOI 10.1136/ijgc-2023-004531

Verify or expand the search:

Other recruiting trials for Ovary Cancer

Currently open trials in the same condition.

NCT07096583 — An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer · Phase 1, PHASE2 · active not recruiting
NCT07213193 — No-Stoma Policy in Advanced Ovarian Cancer Surgery · NA · recruiting
NCT07084168 — Multimedia Aid for Genetic Testing in Gynecologic Oncology · NA · recruiting
NCT06540729 — RC48 in Combination With AK104 and Bevacizumab in OCCC · Phase 2 · recruiting
NCT06556342 — The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women · NA · recruiting

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05256576 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05256576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing